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Background: Due to the hyper-activation of WNT signaling in a variety of cancer types, there has been a strong
drive to develop pathway-specific inhibitors with the eventual goal of providing a chemotherapeutic antagonist of
WNT signaling to cancer patients. A new category of drugs, called epigenetic inhibitors, are being developed that
hold high promise for inhibition of the WNT pathway. The canonical WNT signaling pathway initiates when WNT
ligands bind to receptors, causing the nuclear localization of the co-activator β-catenin (CTNNB1), which leads
to an association of β-catenin with a member of the TCF transcription factor family at regulatory regions of
WNT-responsive genes. The TCF/β-catenin complex then recruits CBP (CREBBP) or p300 (EP300), leading to histone
acetylation and gene activation. A current model in the field is that CBP-driven expression of WNT target genes
supports proliferation whereas p300-driven expression of WNT target genes supports differentiation. The small
molecule inhibitor ICG-001 binds to CBP, but not to p300, and competitively inhibits the interaction of CBP with
β-catenin. Upon treatment of cancer cells, this should reduce expression of CBP-regulated transcription, leading
to reduced tumorigenicity and enhanced differentiation.
Results: We have compared the genome-wide effects on the transcriptome after treatment with ICG-001 (the specific
CBP inhibitor) versus C646, a compound that competes with acetyl-coA for the Lys-coA binding pocket of both CBP
and p300. We found that both drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and
PANC1 pancreatic cancer cells and reverse some tumor-specific changes in gene expression. Interestingly, although the
epigenetic inhibitors affect cell cycle pathways in both the colon and pancreatic cancer cell lines, the WNT signaling
pathway was affected only in the colon cancer cells. Notably, WNT target genes were similarly downregulated after
treatment of HCT116 with C646 as with ICG-001.
Conclusion: Our results suggest that treatment with a general HAT inhibitor causes similar effects on the
transcriptome as does treatment with a CBP-specific inhibitor and that epigenetic inhibition affects the WNT
pathway in HCT116 cells and the cholesterol biosynthesis pathway in PANC1 cells.
Keywords: Epigenetic inhibitor, Histone acetylation, WNT signaling, C646, ICG-001, Colon cancer, Pancreatic cancer,
TCF7L2, Cholesterol biosynthesisBackground
Due to the hyper-activation of WNT signaling in a var-
iety of cancer types [1,2], there has been a strong drive
to develop antagonists of WNT signaling for cancer
treatment. Standard inhibitors of the WNT signaling
pathway include biologic inhibitors, such as small inter-
fering RNAs, antibodies, and recombinant proteins, and
chemical inhibitors, such as NSAIDs, vitamins, and* Correspondence: peggy.farnham@med.usc.edu
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unless otherwise stated.polyphenols, that have fairly general (or unknown) tar-
gets [1,3,4]. However, a new category of drugs to target
the WNT pathway is being developed that holds high
promise as chemotherapeutics. These drugs, called epigen-
etic inhibitors, function to modify chromatin structure.
Chromatin is composed of nucleosomes, which are com-
prised of 146 bp of DNA wrapped around eight core his-
tone proteins (two copies each of H2A, H2B, H3, and H4).
The N terminal tails of the core histones that constitute
the nucleosome are subject to various different types of
modifications that can influence chromatin structure and
either enhance or inhibit the ability of transcription factorsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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histone modifications throughout the genome, in combin-
ation with the pattern of DNA methylation, is called the
epigenome. Recent studies have revealed that different his-
tone modifications are associated with active vs. silenced
chromatin, that different cell types show different epige-
nomic patterns of silenced vs. active chromatin, and that
changes in chromatin structure can have a dramatic effect
on cell proliferation, differentiation, and survival. One
widely studied histone modification is acetylation; histone
acetylation is a critical regulatory mechanism of gene ex-
pression and plays an important role in gene expression.
In fact, acetylation of histone H3 on lysine 27 is the epi-
genetic modification that most precisely identifies distal
regulatory regions that serve as active enhancers [5]. Be-
cause cancer genomes show changes in histone acetylation
patterns, there is great interest in the use of acetylation in-
hibitors that inhibit signaling pathways linked to human
cancers for epigenetic therapy [6].
Drugs that inhibit acetylation are particularly relevant
for inhibition of the WNT pathway. The canonical WNT
signaling pathway initiates when WNT ligands bind to
receptors, resulting in the nuclear localization of the
co-activator β-catenin (CTNNB1), which leads to an as-
sociation of β-catenin with a member of the TCF/LEF
transcription factor family at regulatory regions of WNT-
responsive genes [7,8]. The TCF/β-catenin complex can
interact with co-activators such as CBP (CREBBP) and
p300 (EP300) which function in part through the
acetylation of histone H3 on lysine 27 [5]. Thus, it has
been proposed that the initiation of the WNT signaling
pathway ultimately ends with histone acetylation and aFigure 1 Targeting the WNT pathway using epigenetic inhibitors. WN
β-catenin/p300 complexes to the DNA via a TCF/LEF family member, CBP and
ICG-001 disrupts the interaction of CBP with β-catenin, blocking CBP-driven, b
C646 competes with acetyl-coA for the Lys-coA binding pocket of both CBP a
predicted gene expression differences mediated by β-catenin/CBP vs. β-caten
the various components of the WNT signaling model.relaxing of the chromatin structure, a process neces-
sary for gene activation. The small molecule inhibitor
ICG-001 binds to CBP and competitively inhibits the
interaction of CBP with β-catenin [9,10], with the ex-
pected result of loss of active histone at promoters and
enhancers regulated by TCF/β-catenin/CBP complexes
(Figure 1A). Importantly, ICG-001 does not bind to the
highly related histone acetyltransferase (HAT) p300 and
should not affect the activity of promoters or enhancers
bound by TCF/β-catenin/p300 complexes. Thus, ICG-001
is thought to specifically decrease the expression of only
the subset of WNT target genes regulated by β-catenin/
CBP interactions. These proposed effects of ICG-001 are
in contrast to those of C646 an inhibitor that competes
with acetyl-coA for the Lys-coA binding pocket of p300
(Figure 1B). C646 is very selective for p300 versus six
other unrelated histone acetyltransferases [11]. Although
no direct comparisons have been performed, due to the
mode of action of C646 and because the HAT domains
of p300 and CBP have greater than 90% similarity, it
has been proposed that C646 is a general inhibitor for
both CBP and p300 [11]. Of importance for the role of
ICG-001 as a chemotherapeutic drug, studies suggest that
CBP-driven transcription helps to maintain pluripotency
whereas p300-driven transcription pushes cells toward a
differentiated state [3,12-15]; examples of genes thought
to be regulated by CBP vs. p300 are shown in Figure 1C.
However, the hypothesis that ICG-001 specifically
downregulates only the subset of WNT target genes
involved in proliferation (such as BIRC5 and CCND1)
has not been tested on a genome-wide scale. Because a
derivative of ICG-001 called PRI-724 is now in clinicalT signaling culminates when, upon recruitment of β-catenin/CBP or
p300 activate transcription by acetylating histone H3. (A) Treatment with
ut not p300-driven transcription. (B) In contrast to the effects of ICG-001,
nd p300, preventing HAT activity of both complexes. (C) Examples of
in/p300 complexes [15]. (D) RNA levels in HCT116 and PANC1 cells of
Figure 2 The effects of epigenetic inhibitors on the transcriptome
of HCT116 and PANC1 cells. HCT116 colon cancer cells and PANC1
pancreatic adenocarcinoma cells were treated in duplicate with DMSO
or 10 uM ICG-001 or C646 for 12 or 96 h (12 samples per cell line). Cells
were harvested and RNA was analyzed using Illumina HumanHT-12 v4
expression arrays. Any gene having a detection P value <0.01 in any of
the samples was selected for differential gene analysis; genes having a
differential P value <0.05 were further analyzed. The number of
upregulated (red) and downregulated (green) genes under each
condition for each cell line is shown.
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to have a thorough understanding of the specificity and ef-
fectiveness of this drug. Therefore, we have compared the
genome-wide effects on the transcriptome of ICG-001
versus C646 in two cancer cell lines that constitutively ex-
press the components of the transcription complex that
mediates WNT signaling (Figure 1D).
Results
ICG-001 and C646 have similar effects on the
transcriptome of HCT116 colon cancer cells
Constitutive activation of WNT target genes via a TCF/
β-catenin/CBP complex is thought to be a major driver
of colorectal cancer. Therefore, it has been proposed that
treatment of colon cancer cells with ICG-001 should spe-
cifically inhibit the WNT pathway (by preventing recruit-
ment of the co-activator CBP to TCF/β-catenin target
genes) and reduce the tumorigenicity of the cells. In
support of this hypothesis, Emami et al. [10] have shown
that ICG-001 reduces growth of colon carcinoma cells in
culture and reduces the formation of colon and small in-
testinal polyps in a mouse model system. As noted above,
CBP is highly related to another HAT called p300 and
many studies have shown similar functions for p300 and
CBP [16]. In fact, a ChIP-seq analysis of p300 and CBP in
T98G glioblastoma cells immediately after release from
serum starvation arrest showed that almost all of the CBP
genomic binding sites were also bound by p300 [17].
However under the tested conditions, a small set of
genomic sites were preferentially bound by either CBP
or p300, suggesting that there might be some specificity
in their action. It is also possible that cell type plays a
critical role in specifying CBP vs. p300 contributions to
regulating the transcriptome. For example, approximately
50% of Rubinstein-Taybi syndrome patients have muta-
tions in CBP but only 3% of patients have mutations in
p300 [18]. Of course, functional specificity can also occur
post-DNA binding because the two HATs only share ex-
tensive, but not complete, homology. If, for example, CBP
and p300 recruit different interaction partners they could
have opposite effects on transcription at a given promoter.
In support of this hypothesis, Ma et al. have shown that
both CBP and p300 can bind to the BIRC5 promoter but
they have opposite effects on transcription [19].
To determine if the effects on the transcriptome after
specifically inhibiting CBP are different than the effects
after inhibiting both CBP and p300, we treated HCT116
colon cancer cells with 0.05% DMSO, 10 uM ICG-001,
or 10 uM C646 for 12 and 96 h. Samples were prepared
in replicate and Illumina HumanHT-12 v4 expression
arrays were used to detect changes in gene expression
(Figure 2 and Additional file 1). Genes having a detection
P value less than 0.01 in any of the control or treated
cell populations were selected for further analysis; thisconstituted a total of 15,092 genes from HCT116
cells, of which 3,689 showed differential expression in
drug-treated cells (differential expression P value less
than 0.05). After selecting the significant differentially
expressed genes, the expression fold change was cal-
culated for each gene and Euclidean distance was
used for K-means clustering of expression fold change
(Figure 3). We found that, contrary to our initial ex-
pectations, a very similar response was observed for
both drugs (Additional file 2). Genes that were down-
regulated by both drugs were involved in the cell cycle
and WNT signaling (Figure 3 and Additional file 3). How-
ever, some genes did show drug-specific changes in
HCT116 cells. According to the mechanism of action of
each drug, genes with decreased levels of expression only
after treatment with ICG-001 should be regulated by CBP
but not by p300, whereas genes with decreased levels of
expression only after treatment with C646 but not with
ICG-001 should be regulated by p300 but not by CBP. A
gene ontology analysis of the approximately 400 genes af-
fected only by ICG-001 revealed a strong enrichment for
genes controlling the cell cycle whereas the approximately
AB
Figure 3 Effects of epigenetic inhibitors on gene expression in HCT116 cells. (A) Genes differentially expressed after treatment of HCT116 cells
with ICG-001 or C646 (see Figure 2) were analyzed using Euclidean distance and K-means clustering of expression fold change. (B) Gene ontology
analyses are shown for the genes commonly up- and downregulated by both drugs and for the genes that are downregulated only by one of the
drugs in HCT116 cells. Terms related to the cell cycle are shown in red and terms related to WNT signaling are shown in blue. The numbers 1 to 6 in
the brackets in panel A refer to different clusters that were used in the gene ontology analyses shown in panel B (see Additional file 3).
Gaddis et al. Epigenetics & Chromatin 2015, 8:9 Page 4 of 12
http://www.epigeneticsandchromatin.com/content/8/1/9500 genes only affected by C646 were not related to cell
proliferation. Thus, in HCT116 cells, both drugs have a
broad effect on gene regulation that includes downregula-
tion of genes involved in proliferation control. However,
treatment of colorectal cancer cells with ICG-001 alters
the expression of a greater number of cell cycle-regulated
genes than does treatment with C646.
ICG-001 and C646 have similar effects on the
transcriptome of PANC1 cells
As noted above, the WNT/TCF/β-catenin/CBP path-
way has been proposed to be a major positive regulator
of proliferation of colon cancer cells. Perhaps β-catenin/
CBP complexes play a prominent role in WNT-mediated
gene expression in HCT116 cells (with little contribution
by β-catenin/p300 complexes), explaining why the effects
of ICG-001 were so widespread and why treatment with
the two drugs elicited similar responses. To determine if
ICG-001 has a similar widespread effect on other cancer
cells, we also examined pancreatic cancer cells. Pancreatic
ductal adenocarcinoma, the most common form of pan-
creatic cancer, displays activation of the WNT/β-catenin
pathway [20-25] and is therefore predicted to respond to
treatment with ICG-001. We treated PANC1 cells with
ICG-001 or C646 and analyzed gene expression
(Additional files 1 and 2). Again, we found that ICG-001
and C646 have similar effects on PANC1 cells (Figure 4),
with genes involved in cell cycle regulation being down-
regulated by both drugs (see also Additional file 4). How-
ever, in this case, cell proliferation-related genes were not
enriched categories in gene sets downregulated specifically
by either ICG-001 or C646. Interestingly, in PANC1 cells,the cholesterol biosynthesis pathway was highly enriched
for genes specifically downregulated by ICG-001, suggest-
ing that perhaps genes involved in cholesterol biosynthesis
are specific CBP, but not p300, target genes. In contrast,
p300-specific genes (identified as those responsive only to
C646) appear to be involved in various types of signaling
pathways, including PI3K/AKT signaling which is linked
to cell survival.
To determine if gene responses to the drugs were cell
type-specific, we compared the genes whose expression was
altered by ICG-001 or C646 in both HCT116 and PANC1
cells (a total of 6,732 genes). Genes that were significantly
detected in HCT116 or in PANC1 cells (P value <0.01) and
which had a differential P value <0.05 and a fold change
greater than 1.2 (5,182 genes) were compared using hier-
archical clustering with Euclidean distance and average
linkage measures (Figure 5). We found that although some
genes were altered in a cell type-specific manner, most
genes were similarly affected in both cell types; see
Additional file 5 for a list of the cell type-specific and
cell-type common affected genes. A gene ontology analysis
revealed that the top two categories of genes downregu-
lated by ICG-001 or C646 in both HCT116 and PANC1
cells were oxidative phosphorylation and mitochondrial
dysfunction. Genes that were commonly upregulated by
the drugs in both cell types are involved in pathways such
as death receptor signaling and INOS signaling.
Effectiveness of the epigenetic inhibitors in reverting a
tumor cell phenotype
The ultimate goal of epigenetic therapy is to revert the
transcriptome from a tumor-specific pattern of gene
A
B
Figure 4 Effects of epigenetic inhibitors on gene expression in PANC1 cells. (A) Genes differentially expressed after treatment of PANC1
cells with ICG-001 or C646 (see Figure 2) were analyzed using Euclidean distance and K-means clustering of expression fold change. (B) Gene
ontology analyses are shown for the genes commonly up- and downregulated by both drugs and for the genes that are downregulated only by
one of the drugs in PANC1 cells. Terms related to the cell cycle are shown in red. The numbers 1 to 6 in the brackets in panel A refer to different
clusters that were used in the gene ontology analyses shown in Panel B (see Additional file 4).
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mal cells. To determine the extent to which the epigen-
etic inhibitors ICG-001 and C646 are effective in this
goal, we obtained RNA-seq expression data for 41 normal
and 274 tumor colon cells from the TCGA Consortium.
Using this data, we identified 16,416 genes that were
expressed in either normal or colon samples, using log2
(RSEM+ 1) >2. Of these, 11,824 genes were differentially
expressed (adjusted differential P value <0.001) in the
tumor samples as compared to the normal tissues. ToA
B
Figure 5 ICG-001 and C646 affect many of the same genes in HCT11
both HCT116 or in PANC1 cells (P value <0.01) were analyzed for expression d
P value <0.05 and a fold change greater than 1.2 were analyzed using Euclide
shown for the genes commonly up- or downregulated in HCT116 and PANC
Additional file 5 for a complete gene ontology analysis of the up- and downrdetermine if the drugs were effective in reverting the
expression of these genes back to normal levels, we
compared the set of genes deregulated in the tumors
with the set of genes responsive to the drug treatments,
identifying a set of 2,028 common genes. If the drugs
are having an anti-tumor effect, then genes that are up-
regulated in tumors should be downregulated by the drugs
and genes that are downregulated in tumors should be up-
regulated by the drug. Using a log2(RSEM+ 1) cutoff of 2,
we identified 2,029 genes that showed expression changes6 and PANC1 cells. (A) Genes that were significantly detected in
ifferences caused by drug treatment. All genes having a differential
an distance and hierarchical clustering. (B) Gene ontology analyses are
1 cells by the drugs. Terms related to the cell cycle are shown in red. See
egulated genes.
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to the normal tissues. An analysis of these expression
patterns (Figure 6 and Additional file 6) shows that
many genes had expression changes in the correct dir-
ection as a result of treatment with at least one drug
(that is, a gene that is upregulated in tumors was down-
regulated by a drug or a gene that is downregulated in
tumors was upregulated by a drug). Analysis of four
normal and 125 pancreatic tumor samples revealed a much
smaller set of genes showing expression changes in tumors.
Using a log2(RSEM + 1) cutoff of 2, we identified only
167 genes that showed expression changes (adjusted
P value <0.05) in pancreatic tumor cells, as compared
to the normal tissues. It is unclear as to whether the
small number of differentially expressed genes in the
pancreatic tumors as compared to the colon tumors is
due to real differences in cancer phenotypes, to the small
number of normal pancreatic samples, or other possi-
bilities such as tumor heterogeneity. To increase the num-
ber of analyzed genes, we also obtained a list of 596 genes
that are differentially expressed in normal hTERT-HPNE
pancreatic cells as compared to PANC1 cells [26]. WeHCT116 
381 
340 
T/N ICG C646 
7 
10 
T/N ICG C646 
179 
134 












Figure 6 Epigenetic inhibitors can partially restore a normal
expression pattern to tumor cells. Genes that showed tumor-specific
changes in expression in TCGA colon RNA-seq samples (left), TCGA
pancreatic RNA-seq samples (right, top), plus differentially expressed
genes identified by comparison of normal to tumor pancreatic
cell lines (right bottom) were analyzed for responses to drug
treatments; see Additional file 6. In the T/N columns, green indicates
that the gene was downregulated in the tumor cells whereas red
indicates the gene was upregulated in the tumor cells. The blue
brackets indicate genes that were downregulated in the tumor
cells and upregulated by the drugs (resulting in an expression level
closer to that in normal cells) whereas the black brackets represent
the genes that were upregulated in the tumor cells and downregulated
by the drugs (resulting in an expression level closer to that in normal
cells). The color scale indicates the fold change of gene expression in
HCT116 or PANC1 cells after treatment with ICG-001 (ICG) or C646.examined the responses of the 167 genes that are differ-
entially regulated in normal pancreatic tissue vs. tumors
and the 596 genes that are differentially regulated in
normal HPNE cells grown in culture vs. PANC1 cells to
drug treatment. We found that many of the genes whose
expression is deregulated in pancreatic tumors or PANC1
cells showed appropriate responses to at least one drug
(that is, genes upregulated in tumors or PANC1 were
downregulated by the drugs and genes downregulated
in tumors or PANC1 were upregulated by the drugs)
(Figure 6 and Additional file 6). Thus, treatment with
the epigenetic inhibitors is effective in reverting some
of the tumor-specific transcriptome to a normal pattern.
Direct targeting of a component of the transcription
complex that mediates WNT signaling
As described above, ICG-001 was developed to be a spe-
cific inhibitor of the WNT pathway. We therefore directly
analyzed the WNT pathway using a list of genes previously
implicated as components of this pathway (http://www.
stanford.edu/group/nusselab/cgi-bin/wnt/). We found that
a subset of these proposed WNT target genes were
expressed in HCT116 and/or PANC1 cells and were
significantly affected by treatment with ICG-001 or
C646 (Figure 7 and Additional file 7). The overall trend
of the effects of ICG-001 and C646 on WNT targets
was similar in a given cell line. However, the WNT
pathway-related genes responded quite differently to the
epigenetic inhibitors in the different cell lines. In general,
the response of the genes listed in Figure 1C was more
similar to what was predicted when HCT116 cells were
treated with the epigenetic inhibitors than when PANC1
cells were treated with the drugs. For example, expression
of the transcription factor JUN (which is involved in speci-
fying differentiated phenotypes) is increased by both drugs
in HCT116 but is decreased by both drugs in PANC1.
Conversely, the expression of MYC, a transcription factor
involved in cell proliferation, is reduced by both drugs in
HCT116 but is increased by both drugs in PANC1 cells.
The gene ontology results suggest that ICG-001 and
C646 affect the WNT pathway in HCT116 cells but not
in PANC1 cells. Of course, it is also possible that differ-
ent downstream target genes mediate the WNT pathway
in pancreatic cancer cells as compared to colon cancer
cells. The HATs CBP and p300 are brought to genomic
regulatory elements by the DNA binding protein TCF7L2
via interaction with the bridging protein β-catenin. If
ICG-001 and C646, which block the recruitment or func-
tion of the HAT activity of the co-activators CBP and
p300, are specific inhibitors of the WNT signaling path-
way in PANC1 cells, then targeting TCF7L2 should result
in similar effects on the transcriptome as does drug treat-
ment. In contrast, if the epigenetic inhibitors are in fact
targeting a different pathway in PANC1 cells, then genes
AB
Figure 7 Effects of drug treatments on WNT pathway genes. (A) Shown are the expression changes in previously identified WNT pathway
genes (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/) that have a detection P value <0.01 and a differential P value <0.05 after 96 h of
treatment of HCT116 or PANC1 cells with either ICG-001 (ICG) or C646; see Additional file 7. (B) Shown are the predicted results (based on the
model shown in Figure 1) and the actual responses to the drugs after treatment of HCT116 or PANC1 cells for a set of WNT target genes. In the
prediction column, a red arrow indicates that the gene should have been upregulated by ICG-001 and the green arrow indicates that the gene
should have been downregulated by ICG-001, according to the model. For each cell type, the actual response is shown for both drugs: a red
arrow indicates that expression was increased as predicted by the model, a green arrow indicates expression was decreased as predicted by the
model, a gray arrow indicates that the expression pattern upon treatment did not correspond to the prediction, and an x indicates that the gene
was not expressed in that cell line.
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the set of genes affected by the drugs. To identify genes
affected by direct targeting of a component of the tran-
scriptional complex implicated in WNT regulation, we
used siRNAs to knockdown TCF7L2 in PANC1 cells.
Cells were treated with control siRNAs or siRNAs spe-
cific for TCF7L2 and RNA was analyzed by RNA-seq;
see Additional file 8 for a list of genes affected by
knockdown of TCF7L2. We analyzed the top 1,000
genes that were affected by knockdown of TCF7L2 and
the top 1,000 genes affected by treatment with ICG-001
(Figure 8). Interestingly, there were very few genes af-
fected by reduction of TCF7L2 that were also affected
by ICG-001. Specifically, the WNT pathway was identified
in the set of genes affected upon reduction of TCF7L2
(see Additional file 9 for a complete gene ontology ana-
lysis) but not by treatment with ICG-001 (Figure 4). These
results suggest that in PANC1 cells co-activators other
than CBP cooperate with TCF7L2 to regulate gene expres-
sion and support the hypothesis that the anti-proliferative
effects of ICG-001 in PANC1 cells are not due to inhib-
ition of the WNT pathway.
Discussion
Recent studies have shown large changes in the epige-
nomic patterns in normal vs. cancer cells, suggesting thatepigenetic therapy may be commonly applicable to treat-
ments of various cancers. Drugs that target epigenetic
regulators are being developed [27-29], some of which
are moving into clinical trials. However, the specificity
of action of many of these drugs has not yet been thor-
oughly examined. In particular, genome-wide analyses
of their effects have not been determined. In our study,
we compare the effects of treatment with C646, which
is thought to compete with acetyl-coA for the Lys-coA
binding pocket of both p300 and CBP [11] to the ef-
fects of ICG-001, which specifically binds to CBP and
prevents its interaction with the co-activator β-catenin.
Theoretically, ICG-001 is expected to be of higher specifi-
city than C646 because it should only affect β-catenin/
CBP-driven transcription whereas C646 should affect all
genes regulated by either CBP or p300, regardless of
whether β-catenin is involved. However, it is possible
that ICG-001 has broader effects than anticipated if the
drug affects the ability of CBP to interact with other as-
of-yet unknown co-activators. In addition, we note that
CBP and p300 can acetylate non-histone proteins [30];
thus, both compounds could also have effects on non-
chromatin bound proteins. Although we initially expected
cells to respond differently to C646 and ICG-001, our re-
sults suggest that generally these two drugs have similar
effects on the transcriptome of tumor cells. However, we
AB
Figure 8 In PANC1 cells, treatment with ICG-001 does not affect the same genes as does reduction in levels of TCF7L2. (A) PANC1 cells
were treated with siRNAs to TCF7L2 and RNA-seq was performed; see Additional file 8 for a list of genes affected by knockdown of TCF7L2. The
top 1,000 differentially expressed genes after knockdown of TCF7L2 were compared to the top 1,000 genes identified to be responsive to ICG-001
in PANC1 cells. (B) Gene ontology analyses are shown for the genes commonly up- and downregulated by knockdown of TCF7L2 and treatment
with ICG-001 and genes that are only affected by knockdown of TCF7L2. Terms related to the cell cycle are shown in red and terms related to the
WNT pathway are shown in blue. See Additional file 9 for a complete gene ontology analysis of the different gene sets.
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after epigenetic inhibition.
We observed dramatic effects on the transcriptome
upon treatment of HCT116 colon cancer cells with ei-
ther ICG-001 or C646, with thousands of genes showing
differential expression. Interestingly, the responses to the
two drugs were quite similar overall, with both drugs
causing a reduction in certain genes involved in the WNT
pathway. Because ICG-001 affects only CBP-driven tran-
scription and not p300-driven transcription, these results
suggest that perhaps the majority of the WNT-related
active regulatory elements in HCT116 cells are bound
by β-catenin/CBP complexes. We did identify a set of
approximately 500 genes whose expression was down-
regulated by ICG-001 and not by C646 (these are potential
CBP-specific target genes) and a set of approximately 500
genes whose expression was downregulated by C646 but
not by ICG-001 (these are potential p300-specific target
genes). These results are similar to a previous study of
CBP and p300 in T98G glioblastoma cells that found that
the two factors bound mainly to the same sites but that
some specific binding sites could be identified [17]. Inter-
estingly, the genes specifically responsive to ICG-001 but
not to C646 in HCT116 cells showed enrichment for
cell proliferation-related gene ontology categories. Taken
together, these results suggest that thousands of genes are
regulated both by p300 and CBP (many of which are in-
volved in cell proliferation) and that CBP-specific genes
may also include additional genes that regulate cell prolif-
eration whereas p300-specific genes are involved in other
processes. In general, our results in HCT116 cells supportthe current model implicating WNT-mediated cell signal-
ing as a critical regulator of cancer cell proliferation.
Although the WNT pathway has been implicated in the
development of pancreatic cancer, the studies are not as
extensive as those related to WNT’s role in colon cancer
[20-25]. We show that, in general, the effects of ICG-001
and C646 on the transcriptome of PANC1 cells are similar
to those observed upon treatment of HCT116 cells. For
example, a set of genes involved in cell proliferation show
reduced expression upon treatment of PANC1 with either
ICG-001 or C646. However, we did observe several differ-
ences in the response of PANC1 cells to the epigenetic
inhibitors, as compared to HCT116 cells. First, we found
that many of the enriched gene categories that responded
specifically to ICG-001 treatment of PANC1 cells are
involved in cholesterol biosynthesis. Interestingly, many
cancers have a high dependency on accelerated biogen-
esis and uptake of lipids and cholesterol and inhibition
of these pathways has been proposed to be a therapeutic
opportunity for metabolic targeting of cancer growth
[31,32]. Cholesterol homeostasis in mammalian cells is
maintained in part by a basic-helix-loop-helix family of
transcription factors called the sterol regulatory elem-
ent binding proteins (SREBPs) [33,34]. The SREBP fam-
ily members activate a number of target genes involved
in cholesterol and fatty acid metabolism through binding
to sterol regulatory elements in the promoters of target
genes. In fact, SREBP transcription factors have been
suggested to be novel therapeutic targets [35]. Interest-
ingly, SREBP proteins require interaction with CBP to
mediate transcriptional activation [36]. Thus, the treatment
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interaction between CBP and a SREBP family member,
causing downregulation of genes involved in the choles-
terol biosynthetic pathway (Additional file 10). Second, in
PANC1 cells the WNT pathway was not enriched in
downregulated genes after treatment with either drug
and several critical WNT target genes showed unex-
pected transcriptional responses. Notably, expression of
JUN (which promotes differentiation) was predicted to
be increased upon treatment but in PANC1 cells JUN
expression was decreased (JUN did show the expected
response in HCT116 cells). Similarly, expression of MYC
(which promotes proliferation) was predicted to be de-
creased upon treatment but in PANC1 cells MYC expres-
sion was increased (MYC did show the expected response
in HCT116 cells). The transcriptional response of the
MYC gene was particularly surprising because it is consid-
ered to be a critical mediator of WNT signaling. Upregula-
tion of MYC in PANC1 suggests that the drugs do not
inhibit the WNT pathway in these cells. This hypoth-
esis is supported by our finding that in PANC1 cells
knockdown of TCF7L2, the transcription factor that
brings β-catenin and CBP to regulatory elements to
regulate WNT-responsive genes, does not affect expres-
sion of the same genes as are affected by treatment with
ICG-001. While our work was in progress, another group
reported treatment of pancreatic cancer cells with ICG-
001 [37]. They showed that treatment of PANC1 cells with
10 uM ICG-001 was effective at reducing cell proliferation
in culture and reducing colony formation in soft agar. Al-
though global effects on the PANC1 transcriptome were
not examined in that study, the noted effects on prolifera-
tion are consistent with our finding that cell cycle-related
genes are downregulated in response to ICG-001 and
C646. That study did, however, perform microarray ex-
pression analysis after treatment of a different pancreatic
cancer cell line (AsPC-1) with ICG-001 and found that
569 transcripts were upregulated and 150 transcripts were
downregulated. Because only 117 of the 719 drug-
responsive genes were altered in β-catenin knockdown
cells, they concluded that ICG-001 had a broader effect
than simply as a disrupter of WNT/β-catenin signaling in
AsPC-1 cells.
As noted above, epigenetic inhibitors are considered
promising new drugs for cancer treatment. One current
clinical trial employs PRI-724, a derivative of ICG-001,
in combination with gemcitabine in patients with advanced
or metastatic pancreatic adenocarcinoma (NCT01764477).
Gemcitabine is considered a first-line treatment for pancre-
atic adenocarcinoma but has poor overall efficacy because
pancreatic cancer cells develop resistance to the drug [38].
While investigating the pathways that lead to drug resist-
ance, the transcriptional regulator NUPR1 (also known as
anti-apoptotic protein p8 or Candidate of Metastasis-1)was identified as being involved in the acquisition of gem-
citabine resistance by pancreatic cancer cells [39]. NUPR1
normally functions as a stress response gene in the pan-
creas, but it has been shown to contribute to metastasis,
anti-apoptotic activity and pancreatic cancer development
[40,41]. Interestingly, our genome-wide analyses identified
NUPR1 as one of the top upregulated genes after treatment
of PANC1 cells with ICG-001. The upregulation of NUPR1
by ICG-001 may explain why ICG-001 plus gemcitabine
did not increase overall lifespan in an in vivo pancreatic
cancer cell xenograft model [37]. Although the mechanism
by which NUPR1 promotes oncogenesis and/or drug
resistance in pancreatic cells is not yet known, NUPR1
has been shown to form a complex with p300 and TP53
to upregulate and promote cytoplasmic translocation of
CDKN1A (p21) in breast cancer cells [42]. Although
nuclear p21 is a negative regulator of cell cycle progres-
sion, studies have associated cytoplasmic p21 with drug
resistance and oncogenic activity in breast and testicular
cancer [43-45]. Vincent et al. [44] showed that treatment
of NUPR1-expressing cells with PI3K-AKT inhibitors
could reverse cytoplasmic p21 localization and re-sensitize
cells to doxorubicin. Importantly, studies have also shown
that inhibition of the PI3K-AKT pathway in pancreatic
cancer helps re-sensitize cells to gemcitabine [46,47].
Thus, adding a PI3K-AKT inhibitor to the combined
usage of ICG-001 plus gemcitabine may be the most ef-
fective treatment combination. However, it should also
be noted that C646 caused only a modest increase in
NUPR1 in PANC1 cells and that C646, but not ICG-
001, specifically inhibited the PI3K-AKT pathway (see
Figure 4). Taken together, these results suggest that per-
haps C646 plus gemcitabine would be more effective than
ICG-001 plus gemcitabine in the treatment of pancreatic
cancer.
Conclusions
We have compared the genome-wide effects on the tran-
scriptome of ICG-001 (a specific CBP inhibitor) versus
C646 (a compound that competes with acetyl-coA for
the Lys-coA binding pocket of both CBP and p300). We
found that ICG-001 has a similar broad specificity as
C646 in HCT116 colon cancer, with both drugs decreas-
ing the expression of cell cycle-related and WNT pathway
genes. In contrast, ICG-001 and C646 affect cell cycle-
related genes but do not result in appropriate responses of
critical WNT target genes in PANC1 cancer cells. The ef-
fects of ICG-001 on PANC1 cells and comparison to gene
expression patterns in TCF7L2 knockdown cells suggests
that ICG-001 inhibits proliferation of pancreatic cancer
cells via a mechanism different than the WNT pathway.
Gene ontology analyses point toward disruption of
SREBP-CBP functional interactions as a possible cause of
the anti-proliferative function of ICG-001 in pancreatic
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fective at reversing some tumor-specific changes in gene
expression that are observed in colon or pancreatic tumor
cells.Methods
Cell growth conditions
The human cell lines HCT116 (ATCC #CCL-247) and
PANC1 (ATCC #CRL-1469) were obtained from the
American Type Culture Collection. HCT116 and PANC1
cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin. Michael Kahn (University of
Southern California) provided ICG-001 and C646 was
obtained from VWR (catalog # 102516–240). Cells were
treated with 10 uM ICG-001, 10 uM C646, or 0.05%
DMSO and collected after 12 or 96 h. Cells for the 12-h
treatments were grown to 70% confluency before addition
of the drugs or DMSO. Cells for the 96-h treatments were
grown at 40% to 50% confluency before addition of the
drugs or DMSO and were passaged before they could
reach 90% confluency. New media and drugs were added
every 24 h. After treatment, gene expression was analyzed
using Illumina BeadChips.Microarray RNA expression
Total RNA was collected using Trizol according to the
manufacturer’s instructions (Life Technologies). To con-
firm RNA samples were not degraded, RNA quality was
checked with the Experion StdSens kit (Bio-Rad) prior
to amplification and labeling. The Illumina TotalPrep
RNA Amplification Kit (Life Technologies catalog #
AMIL1791) was used according to the manufacturer’s
instructions to amplify and label RNA samples for Illu-
mina array hybridization. Labeled RNAs were analyzed
with Illumina HT-12 v4 Expression BeadChips (Catalog #:
BD-103-0204) with the Direct Hybridization Assay and
then scanned on an Illumina HiScan (catalog # BD-103-
0604). The data were analyzed and exported from Illumina’s
GenomeStudio software using quantile normalization with-
out background subtraction. Each drug/DMSO treatment
and time point was performed using two independent bio-
logical replicates. The correlation between replicates was
calculated to ensure that the data were reproducible, repli-
cate samples were averaged together and genes with a de-
tection P value <0.01 were considered for further analysis.
Differential expression analysis was performed using Illumi-
na’s custom differential expression error model, which as-
sumes a normal distribution of the target signal intensity
and takes into account biological variation, non-specific
biological variation, and technical error. For more detail on
Illumina’s custom error model, see GenomeStudio Gene
Expression Module v1.0 User Guide (pages 103 and 104).Genes with a differential expression P value <0.05 were
considered to be significantly differentially expressed.
TCF7L2 knockdown
TCF7L2 knockdown was performed in triplicate by
siRNA transfection. Transfections were performed using
Lipofectamine RNAiMax (Life Technologies) according
to manufacturer’s instructions. A final concentration of
40nM siRNAs targeting either TCF7L2 (catalog # 4392420,
Life Technologies) or a non-specific negative control
siRNA (catalog # AM4611, Life Technologies) were used
using reduced serum OptiMEM media (Life Technologies).
Media was changed 12 h post transfection and total RNA
was collected 48 h post transfection using Trizol ac-
cording to manufacturer’s instructions (Life Technologies).
Knockdown efficiency was detected using RT-qPCR and
then samples were analyzed by RNA-seq.
RNA-Seq
Total RNA was used for polyA+ RNA selection using
oligo-dT beads and subjected to library construction by
True-Seq library preparation kits (Illumina), followed by
Illumina HiSeq2000 sequencing. The RNA-seq reads
were aligned to the human genome hg19 using Bowtie2
with ultrasensitive parameters. The RNA-seq reads were
counted over gene exons using HTSeq [48]. EdgeR was
used for statistical analyses of siControl and siTCF7L2
samples, and a fold change of 2 was used to call the dif-
ferentially expressed genes [49].
Ingenuity pathway analysis
Gene network diagrams in Additional file 10 were created
through use of IPA. The expression data were analyzed
through the use of QIAGEN’s Ingenuity® Pathway Ana-
lysis (IPA®, QIAGEN Redwood City, www.qiagen.com/
ingenuity). For each subset of genes a core analysis was
run with parameters set to consider only direct relation-
ships and relationships between molecules that have been
experimentally observed. The reference gene set used for
P value calculations was the Ingenuity Knowledge Base
(genes only).
Data access
Expression array analyses for control and treated cells and
RNA-seq datasets for TCF7L2 knockdown experiments
have been deposited in GEO (GSE64039 and GSE63776).
The TCGA RNA-seq can be downloaded at https://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp.
Additional files
Additional file 1: (A) Gene expression analysis after drug treatment
of HCT116 cells. (B) Gene expression analysis after drug treatment of
PANC1 cells.
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